睿智医药(300149) - 2023 Q3 - 季度财报(更新)

Key Financial Data Key Accounting Data and Financial Indicators The company experienced significant performance decline in Q3 2023, with revenue down 16.39% and a net loss of ¥16.23 million, alongside a YTD revenue decrease of 18.02% and a 10.58% reduction in total assets Q3 & YTD 2023 Key Financial Metrics | Indicator | Q3 2023 (¥) | YoY Change | YTD 2023 (¥) | YoY Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 288,723,816.62 | -16.39% | 846,178,408.68 | -18.02% | | Net Profit Attributable to Shareholders | -16,227,230.17 | -124.29% | -31,322,915.93 | -103.06% | | Net Profit after Non-recurring Items | -16,572,416.06 | -126.49% | -38,771,246.00 | -240.61% | | Basic EPS (¥/share) | -0.03 | -123.08% | -0.06 | -102.93% | | Operating Cash Flow Net | -- | -- | 86,805,910.98 | 234.83% | Balance Sheet Position as of Q3 2023 End | Indicator | End of Q3 2023 (¥) | Change from YE 2022 | | :--- | :--- | :--- | | Total Assets | 3,405,045,114.58 | -10.58% | | Equity Attributable to Shareholders | 2,324,254,943.69 | -0.91% | Non-recurring Profit and Loss Items Net non-recurring gains for the first nine months of 2023 totaled ¥7.45 million, primarily from government subsidies and fair value gains, partially offset by asset disposal losses YTD 2023 Non-recurring Profit and Loss (Unit: ¥) | Item | YTD Amount | | :--- | :--- | | Non-current asset disposal loss | -1,546,018.11 | | Government grants | 4,592,010.91 | | Gains from entrusted investments | 557,262.60 | | Fair value change gains of associate's investments | 4,791,846.94 | | Other non-operating income/expense | 258,749.71 | | Total (after tax and minority interest) | 7,448,330.07 | Analysis of Major Changes in Financial Data Significant financial fluctuations were primarily due to the prior year's subsidiary disposal, impacting cash, taxes, and investment income, alongside operational changes like increased fixed assets and reduced debt Significant Balance Sheet Changes (vs. YE 2022) | Item | Change | Reason | | :--- | :--- | :--- | | Monetary Funds | -61.38% | Received proceeds from subsidiary sale in prior year | | Fixed Assets | +40.83% | Transfer from construction in progress as projects completed | | Construction in Progress | -42.34% | Transfer to fixed assets upon project completion | | Short-term Borrowings | -47.83% | Repayment of bank loans | | Long-term Borrowings | -73.43% | Repayment of bank loans | | Taxes Payable | -87.41% | High taxes payable in prior period due to gain on subsidiary disposal | Significant Income Statement Changes (YTD YoY) | Item | Change | Reason | | :--- | :--- | :--- | | Administrative Expenses | -34.70% | Reduction following the disposal of the prebiotics business in 2022 | | Financial Expenses | +128.26% | Reduced foreign exchange gains due to currency fluctuations | | Investment Income | -99.25% | Prior year included a large gain from the disposal of a subsidiary | | Income Tax Expense | -98.16% | High tax expense in prior year due to gain on subsidiary disposal | Significant Cash Flow Statement Changes (YTD YoY) | Item | Change | Reason | | :--- | :--- | :--- | | Net Operating Cash Flow | +234.83% | Prior year had high cash outflow from tax payments on subsidiary disposal | | Net Investing Cash Flow | -102.46% | Prior year included large cash inflow from subsidiary disposal | | Net Financing Cash Flow | +49.41% | Prior year had larger repayment of bank loans | Shareholder Information Common Shareholder Holdings As of Q3 2023, the company had 27,799 common shareholders, with the top ten holding 52.69% of shares, including two entities controlled by the same director and several using margin financing accounts - The total number of common shareholders at the end of the reporting period was 27,799[9] Top 10 Shareholders and Holdings | Shareholder Name | Stake | Number of Shares | | :--- | :--- | :--- | | North Sea Baben Venture Capital Co., Ltd. | 13.69% | 68,441,800 | | Hangzhou Cixuan Liangjia Investment Mgmt. | 10.24% | 51,185,660 | | Shanghai Ruiyun Enterprise Mgmt. Center | 5.41% | 27,046,221 | | Hong Kong Securities Clearing Company Ltd. | 5.36% | 26,804,098 | | MEGA STAR CENTRE LIMITED | 4.54% | 22,711,333 | | Zeng Xianjing | 2.55% | 12,755,275 | | Shaoguan Baotao Enterprise Mgmt. Co., Ltd. | 2.38% | 11,878,300 | | Hunan Jiaquan Business Co., Ltd. | 2.27% | 11,362,818 | | Zhang Daocai | 1.58% | 7,908,340 | | Shanghai Ruizhao Enterprise Mgmt. Center | 1.47% | 7,334,408 | - Shanghai Ruiyun Enterprise Management Center and Shanghai Ruizhao Enterprise Management Center are both controlled by company director Mr. Hui Xin and his family[10] Other Important Matters Other Important Matters The company reported no other significant matters requiring disclosure for the reporting period - The report states that there are no other significant matters applicable for disclosure[12] Quarterly Financial Statements Financial Statements This section presents the unaudited consolidated financial statements as of September 30, 2023, including the Balance Sheet, year-to-date Income Statement, and Cash Flow Statement Consolidated Balance Sheet As of September 30, 2023, total assets were ¥3.41 billion, down from ¥3.81 billion, primarily due to decreased cash, while total liabilities reduced to ¥1.06 billion from ¥1.44 billion Consolidated Balance Sheet Summary (Unit: ¥) | Item | Sep 30, 2023 | Jan 1, 2023 | | :--- | :--- | :--- | | Total Current Assets | 813,578,908.14 | 1,280,359,412.36 | | Total Non-current Assets | 2,591,466,206.44 | 2,527,577,729.35 | | Total Assets | 3,405,045,114.58 | 3,807,937,141.71 | | Total Current Liabilities | 503,310,150.71 | 732,030,937.52 | | Total Non-current Liabilities | 553,200,398.30 | 705,904,897.14 | | Total Liabilities | 1,056,510,549.01 | 1,437,935,834.66 | | Total Equity | 2,348,534,565.57 | 2,370,001,307.05 | Consolidated Income Statement (YTD) For the first nine months of 2023, the company reported a net loss of ¥31.32 million, a reversal from a ¥1.02 billion profit in 2022, driven by an 18% revenue decrease and the absence of prior year's investment income Consolidated Income Statement Summary (YTD, Unit: ¥) | Item | YTD 2023 | YTD 2022 | | :--- | :--- | :--- | | Operating Revenue | 846,178,408.68 | 1,032,237,378.52 | | Operating Cost | 635,860,315.07 | 660,310,195.89 | | Operating Profit | -24,807,831.78 | 1,398,557,321.16 | | Investment Income | 10,264,158.92 | 1,359,661,265.46 | | Net Profit (Loss) | -31,468,599.80 | 1,023,227,946.22 | | Net Profit (Loss) Attributable to Parent | -31,322,915.93 | 1,023,391,828.88 | Consolidated Cash Flow Statement (YTD) For the first nine months of 2023, net operating cash flow improved to ¥86.81 million, while investing activities used ¥31.92 million and financing activities used ¥356.90 million, resulting in a ¥295.34 million decrease in cash and equivalents Consolidated Cash Flow Statement Summary (YTD, Unit: ¥) | Item | YTD 2023 | YTD 2022 | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 86,805,910.98 | -64,380,653.93 | | Net Cash Flow from Investing Activities | -31,916,705.64 | 1,295,554,689.49 | | Net Cash Flow from Financing Activities | -356,901,386.10 | -705,492,361.03 | | Net Increase in Cash & Equivalents | -295,344,369.01 | 550,636,092.78 | Audit Report The financial statements presented in this third-quarter report remain unaudited by an independent accounting firm - The company's third quarter report is unaudited[19]